Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics
July 31 2023 - 3:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced the launch of a new mini documentary as part of an
ongoing campaign in support of World Health Day. The film showcases
the Company’s recently unveiled Enzyme-Catalyzed Oligonucleotide
(ECO) Synthesis™ technology, a propriety new synthesis platform
that is being developed to enable the manufacture of ribonucleic
acid interference (RNAi) therapeutics at scale and built around
Codexis’ world-leading CodeEvolver® technology.
“Codexis is at a unique inflection point in its 20-year history.
Building upon our existing strength in enzyme engineering, we
believe that we have identified a series of high-impact programs
where our enzymes and expertise can drive meaningful differences
for our customers, and ultimately patients,” said Stephen Dilly,
MBBS, PhD, President and Chief Executive Officer of Codexis. “Our
ECO Synthesis™ technology provides us the potential to create
significant value across the healthcare landscape by enabling
large-scale manufacture of RNAi therapeutics, an exploding class of
medicines being developed to address significant diseases, such as
cardiovascular disease, Alzheimer’s disease and cancer. If we are
successful, Codexis will enable the commercial-scale production of
RNAi therapeutics, potentially impacting hundreds of millions of
patients on a global scale.”
Codexis’ ECO Synthesis™ technology is a proprietary new
synthesis platform that is being developed to support the
manufacture of RNAi therapeutics by efficiently synthesizing short
inhibitory RNA (siRNA) oligonucleotide sequences. By replacing
conventional chemical processes with enzymatic methods, ECO
Synthesis™ technology is designed to address the scalability
limitations and high volumes of hazardous waste historically
associated with oligonucleotide manufacturing.
The Company plans to demonstrate gram-scale synthesis of its ECO
Synthesis™ technology by the end of 2023, which will enable
pre-commercial testing with select customers in 2024 before its
planned commercial launch. The ECO Synthesis™ technology platform
is where Codexis’ core technical competency and existing commercial
infrastructure come together, positioning the Company to
potentially provide significant value in a market facing
substantial challenges of scale to meet future anticipated demand
as the industry aims to provide much-needed RNAi therapeutics.
For more information on Codexis, ECO Synthesis™ technology and
to view the film, please click here.
About Codexis
Codexis is a leading enzyme engineering company leveraging its
proprietary CodeEvolver® technology platform to discover,
develop and enhance novel, high-performance enzymes and other
classes of proteins. Codexis enzymes solve for real-world
challenges associated with small molecule pharmaceuticals
manufacturing and nucleic acid synthesis, and the Company is
currently developing its proprietary ECO Synthesis™ platform to
enable the scaled manufacture of RNAi therapeutics through an
enzymatic route. Codexis’ unique enzymes can drive improvements
such as higher yields, reduced energy usage and waste generation,
improved efficiency in manufacturing and greater sensitivity in
genomic and diagnostic applications. For more information,
visit www.codexis.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. In some cases, you can identify forward-looking statements
by terminology such as “aim,” “anticipate,” “assume,” “believe,”
“contemplate,” “continue,” “could,” “design,” “due,” “estimate,”
“expect,” “goal,” “intend,” “may,” “objective,” “plan,”
“positioned,” “potential,” “predict,” “seek,” “should,” “suggest,”
“target,” “on track,” “will,” “would” and other similar expressions
that are predictions of or indicate future events and future
trends, or the negative of these terms or other comparable
terminology. To the extent that statements contained in this press
release are not descriptions of historical facts, they are
forward-looking statements reflecting the current beliefs and
expectations of management, including, but not limited to, the
potential of Codexis’ ECO Synthesis™ platform to create value for
Codexis and its customers by enabling commercial-scale manufacture
of RNAi therapeutics; whether a significant market for RNAi
therapeutics will develop; whether and if Codexis is able to
demonstrate gram-scale synthesis of its ECO Synthesis™ technology
by the end of 2023 and begin pre-commercial testing for select
customers in 2024; and whether Codexis will be able to
commercialize its ECO Synthesis™ technology and whether it will be
able to do so in 2025. You should not place undue reliance on these
forward-looking statements because they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond Codexis’ control and that could materially affect actual
results. Factors that could materially affect actual results
include, among others: Codexis’ dependence on its licensees and
collaborators; Codexis’ ability to successfully develop its ECO
Synthesis™ technology; if any of its collaborators terminate their
development programs under their respective license agreements with
Codexis; Codexis may need additional capital in the future in order
to expand its business; Codexis’ dependence on a limited number of
products and customers, and potential adverse effects to Codexis’
business if its customers’ products are not received well in the
markets; whether the end markets for Codexis’ customers’ products
develop and remain viable; if Codexis is unable to develop and
commercialize new products for its target markets; if competitors
and potential competitors who have greater resources and experience
than Codexis develop products and technologies that make Codexis’
products and technologies obsolete; and market and economic
conditions may negatively impact Codexis business, financial
condition and share price. Additional information about factors
that could materially affect actual results can be found in
Codexis’ Annual Report on Form 10-K for the year ended December 31,
2022 filed with the Securities and Exchange Commission (“SEC”) on
February 27, 2023 and in Codexis’ Quarterly Report on Form 10-Q for
the quarter ended March 31, 2023 filed with the SEC on May 4, 2023,
including under the caption “Risk Factors,” and in Codexis’ other
periodic reports filed with the SEC. Codexis expressly disclaims
any intent or obligation to update these forward-looking
statements, except as required by law. Codexis’
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(781) 572-1147media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Jul 2023 to Jul 2024